Home » Market News » DirectorsTalk Highlights » Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)
Hardman & Co

Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)

Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains how Arix differs from other investment vehicles, how it has performed well since it released its interim results, trading relative to the NAV, narrowing the discount, the risks involved and what to expect from the company looking forward.

Questions we ask Dr Martin Hall:

Q1: Can you tell us what Arix does and how it differs from other investment vehicles?
Q2: The shares of Arix Bioscience have performed well since it released its interim results for 2020. Can you say what has been behind this movement?
Q3: So, how are the shares trading relative to the NAV?
Q4: What do you think will make this discount narrow?
Q5: What are the risks?
Q6: What is coming up in the near future?

Arix Bioscience is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.